1
Jones Peter, Pryde David Cameron, Tran Thien Duc: 3 -deazapurine derivatives as tlr7 modulators. Pfizer, Jones Peter, Pryde David Cameron, Tran Thien Duc, DROUIN Stéphane, August 23, 2007: WO/2007/093901 (49 worldwide citation)

The present invention relates to immune response modifiers of Formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhib ...


2
Jones Peter, Pryde David Cameron: 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c. Pfizer, Jones Peter, Pryde David Cameron, DROUIN Stéphane, November 9, 2006: WO/2006/117670 (41 worldwide citation)

This invention relates to purine derivatives, to processes for their preparation, to compositions containing them and to their use. The present invention provides compounds of formula (I) wherein R1, R2, R3, R9, R9a and Y are defined in the description. More particularly, the present invention relat ...


3
Barber Christopher Gordon, Blakemore David Clive, Kinnaird James Welsh Auld, Pryde David Cameron: Chemical compounds. Pfizer, Barber Christopher Gordon, Blakemore David Clive, Kinnaird James Welsh Auld, Pryde David Cameron, DROUIN Stéphane, July 27, 2006: WO/2006/077499 (26 worldwide citation)

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, m and n are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the tre ...


4
Barber Christopher Gordon, Fenwick David Roy, Pryde David Cameron, Stephenson Peter Thomas: Pyrrolidine derivatives as modulators of chemokine ccr5 receptors. Pfizer, Barber Christopher Gordon, Fenwick David Roy, Pryde David Cameron, Stephenson Peter Thomas, DROUIN Stéphane, October 18, 2007: WO/2007/116313 (19 worldwide citation)

The present invention provides compounds of formula (I) wherein R1 to R6 and m are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of var ...


5
BELL Andrew Simon, GARDNER Iain Brian, PRYDE David Cameron, WAKENHUT Florian Michel, GIBSON Karl Richard: INHIBITEURS DE LA RÉPLICATION DU VIH, INHIBITORS OF HIV REPLICATION. Pfizer, BELL Andrew Simon, GARDNER Iain Brian, PRYDE David Cameron, WAKENHUT Florian Michel, GIBSON Karl Richard, DROUIN Stephane D, May 24, 2012: WO/2012/066442 (9 worldwide citation)

The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.


6
Jones Peter, Pryde David Cameron, Tran Thien Duc: Imidazopyridinones. Pfizer, Jones Peter, Pryde David Cameron, Tran Thien Duc, DROUIN Stéphane, February 12, 2009: WO/2009/019553 (3 worldwide citation)

The invention relates to imidazopyridinones, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. By activating TLRs, it should be possible to induce or stimulate immune cells to mount an immune response. In partic ...


7

8
Barber Christopher Gordon, Cook Andrew Simon, Maw Graham Nigel, Pryde David Cameron, Stobie Alan: Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase. Pfizer, Barber Christopher Gordon, Cook Andrew Simon, Maw Graham Nigel, Pryde David Cameron, Stobie Alan, Pfizer, RUDDOCK Keith S, January 10, 2002: WO/2002/002513

The invention provides compounds of formula I wherein R?1¿ is optionally substituted C¿1?-¿6?alkyl, optionally substituted C¿3-7? cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; n is 0, 1 or 2; and Y is -NR?18¿S(O)¿u?R?19¿ or a group shown below.


9
Challenger Stephen, Cook Andrew Simon, Gillmore Adam Thomas, Middleton Donald Stuart, Pryde David Cameron, Stobie Alan: N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad. Pfizer, Challenger Stephen, Cook Andrew Simon, Gillmore Adam Thomas, Middleton Donald Stuart, Pryde David Cameron, Stobie Alan, Pfizer, sRUDDOCK Keith S, October 10, 2002: WO/2002/079143

The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R?1¿ is optionally substituted C¿1-6?alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C¿1-6?alkoxy, -NR¿2? R?3¿ or - NR?4¿SO¿2?R?5¿; X is the linkage -(CH¿2 ...


10
Pryde David Cameron, Stupple Paul Anthony: 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors. Pfizer, Pryde David Cameron, Stupple Paul Anthony, HIRSCH Denise, June 29, 2006: WO/2006/067584

The present invention provides compounds of formula (I) R3, (I) wherein R1, R2, R3 and R4 are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treat ...